The results of the study showed that atezolizumab+carboplatin+nab-paclitaxel(A+CnP) for first-line treatment of patients with EGFR/ALK wild-type nsq-NSCLC showed a better benefit in both OS (median OS: 18.6 months vs 13.9 months) and PFS (median PFS:7.0 months vs 5.5 months) compared to chemotherapy, with no new occurrence of AEs (47). This evidence concerns the gene ALK and non-small cell lung carcinoma.